AstraZeneca details non-executive board changes

AstraZeneca PLC reported upcoming changes to its Board of Directors.

Rhea-AI Filing Summary

AstraZeneca PLC reported upcoming changes to its Board of Directors. Non-Executive Director Nazneen Rahman will retire from the Board at the conclusion of the Company’s AGM on 9 April 2026, after serving since 2017 in several key committee roles.

At the same AGM, Tony Mok will become Chair of the Sustainability Committee and join the Nomination and Governance Committee, while Birgit Conix will join the Sustainability Committee. The company highlights Rahman’s contributions to science, sustainability and governance during her tenure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board changes did AstraZeneca (AZN) announce in this Form 6-K?

AstraZeneca announced that Non-Executive Director Nazneen Rahman will retire from the Board at the AGM on 9 April 2026. The company also detailed new committee roles for Tony Mok and Birgit Conix effective after that meeting.

When will Nazneen Rahman retire from the AstraZeneca (AZN) Board?

Nazneen Rahman will retire from AstraZeneca’s Board at the conclusion of the AGM on 9 April 2026. She has served since 2017, contributing to the Science, Sustainability, Remuneration, and Nomination and Governance Committees in multiple leadership roles.

What new role will Tony Mok take on at AstraZeneca (AZN)?

At the conclusion of the AGM on 9 April 2026, Tony Mok will become Chair of the Sustainability Committee and join the Nomination and Governance Committee. He will succeed Nazneen Rahman as leader of the Board’s Sustainability oversight work.

What committee change was announced for Birgit Conix at AstraZeneca (AZN)?

Following the AGM on 9 April 2026, Birgit Conix will become a member of the Sustainability Committee. This change expands her responsibilities on the Board, supporting AstraZeneca’s ongoing focus on sustainability within its governance structure.

How long has Nazneen Rahman served on the AstraZeneca (AZN) Board?

Nazneen Rahman has served as a Non-Executive Director since 2017. During this period she chaired the Science Committee from 2017 to 2023, led the Sustainability Committee since 2021, and also served on the Remuneration and Nomination and Governance Committees.

What areas of expertise did Nazneen Rahman contribute to AstraZeneca (AZN)?

AstraZeneca notes that Nazneen Rahman contributed specialist experience in genetics research and translation, sustainable healthcare, and a strong commitment to open science and science communication. These skills supported the Board’s work across its science and sustainability-focused committees.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 06:45 AM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of February 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Directorate change

 24 February 2026

Non-Executive Board Changes

AstraZeneca PLC announced today that Non-Executive Director Nazneen Rahman will retire from the Board having joined in 2017. This will take effect at the conclusion of the Company's AGM on 9 April 2026.

The Company also announced today that at the conclusion of the Company's AGM on 9 April 2026:

●       Tony Mok will succeed Nazneen Rahman as Chair of the Sustainability Committee and become a member of the Nomination and Governance Committee; and

●       Birgit Conix will become a member of the Sustainability Committee.

Michel Demaré, Chair of AstraZeneca, said "On behalf of the whole Board, I would like to thank Nazneen Rahman for the significant contributions she has made to our work as a Board, as well as the insights, experience and leadership she brought to our Board Committees. Nazneen has been with us since 2017 and we have benefited from her specialist experience in genetics research and translation, sustainable healthcare as well as her passion for open science and science communication. Nazneen has been a member of the Science Committee throughout her tenure, chairing it from 2017 to 2023, and has been Chair of the Sustainability Committee since its establishment in 2021. She has also served on the Remuneration Committee and Nomination and Governance Committees."

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 24 February 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary